Clinical trials: Antiviral Agents
Anemia, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo for the treatment of anemia in AIDS (Acquired Immunodeficiency Syndrome) patients with anemia that is a result of this disease…
- Trial name
- NCT00269945
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients.
- Conditions
- Corona Virus Infection, Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome, Coronavirus Infection
- Trial name
- COVID-19_LF (NCT04412395)
- Testing
- Lactoferrin (Apolactoferrin)
- Where
- 4 sites in Egypt
- Volunteers
- 516 people
- Sponsor
- National Research Centre, Egypt
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
HIV-1 Infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
This is a phase I, open-label, dose-escalation study to investigate short-term safety, pharmacokinetics, and antiviral activity of UB-421 SC with 4 weekly doses in treatment naive HIV-1 infected patients.
- Trial name
- NCT04620304
- Testing
- UB-421 SC(dB4C7C22-6 mAb)
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- United BioPharma
Chronic HBV Infection
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
The primary objectives of this study are to evaluate the safety and efficacy of GS-4774 in adults with chronic hepatitis B (CHB) viral infection who have been virally suppressed with an oral antiviral (OAV) medication.
- Trial name
- NCT01943799
- Testing
- GS-4774, OAV Regimen
- Where
- 17 sites in United States, New Zealand
- Volunteers
- 178 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients
This study will evaluate the drop in viral load over 10 days of treatment with S-1360 versus placebo in HIV-infected patients who have not previously taken anti-HIV medications.
- Trial name
- NCT00046332
- Testing
- GW810781
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Influenza A, Influenza B
Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death.
- Trial name
- NCT02287467
- Testing
- Intravenous hyperimmune immunoglobulin (IVIG)
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 329 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, Chronic
Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels
Multicenter, Open-label, Single arm Trial with Matched Historical controls. Male and female adults with compensated liver cirrhosis due to chronic hepatitis B virus infection who have low-level viremia.
- Trial name
- ATTACH (NCT04780204)
- Testing
- Treatment
- Where
- 10 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Asan Medical Center
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of combination zidovudine (AZT) and PMEA (adefovir) therapy.
- Trial name
- NCT00002326
- Testing
- Adefovir, Zidovudine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
HIV Infections
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir ) when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients with advanced HIV disease.
- Trial name
- NCT00002115
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings
SHARP-C is an observational cohort study investigating the effect of direct-acting antiviral (DAA) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use.
- Trial name
- SHARP-C (NCT03343925)
- Where
- 4 sites in Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Chronic Hepatitis C
Re-treatment of HCV Following DAA Failure
HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and velpatasvir [VEL]).
- Trial name
- NCT03483987
- Testing
- Sof+Ledi+R arm, Sof+Ledi+R+Peg-IFN arm, Sof+Dacla+R arm
- Where
- 2 sites in India
- Volunteers
- 18 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient…
- Trial name
- NCT00000981
- Testing
- Fiacitabine
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis b
Stopping Antiviral Treatment in Chronic Hepatitis B
Chronic hepatitis B (CHB) infection affected 292 million individuals in the world, translating to about 3.9% of global prevalence. Up to 40% of patients with CHB will develop liver-related complications.
- Trial name
- NCT04431245
- Testing
- Entecavir
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- The University of Hong Kong
Cytomegalovirus Infections, Adenovirus Infection
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in…
- Conditions
- Cytomegalovirus Infections, Adenovirus Infection, EBV Infection
- Trial name
- ACES (NCT03475212)
- Testing
- Virus Specific T-cell (VST) infusion
- Where
- 30 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
Chronic Hepatitis C
SR-BI and Antiviral Treatment Response in HCV
The scavenger receptor type B class I (SR-BI) is a receptor for high-density lipoproteins (HDL) and one of entry factors for hepatitis C virus (HCV).
- Trial name
- NCT02714712
- Testing
- Peginterferon alfa-2a
- Volunteers
- 309 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Hepatitis C Infection, Thrombocytopenia
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
- Trial name
- NCT01153919
- Testing
- romiplostim, ribavirin, PEG-interferon alfa-2a
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Southern California
Influenza
Influenza Challenge Study of VIS410 in Healthy Volunteers
A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).
- Trial name
- NCT02468115
- Testing
- VIS410
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Visterra, Inc.
HIV Infections
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally.
- Trial name
- NCT00002014
- Testing
- Zidovudine, Didanosine
- Where
- 4 sites in United States
- Sponsor
- Glaxo Wellcome
Hepatitis C, Chronic
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin, Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.
- Trial name
- DARE-C (NCT01743521)
- Testing
- TPV/PEG-IFN/RBV
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Kirby Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.